Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Summarizing performance for genome scale measurement of miRNA: reference samples and metrics.

Pine PS, Lund SP, Parsons JR, Vang LK, Mahabal AA, Cinquini L, Kelly SC, Kincaid H, Crichton DJ, Spira A, Liu G, Gower AC, Pass HI, Goparaju C, Dubinett SM, Krysan K, Stass SA, Kukuruga D, Van Keuren-Jensen K, Courtright-Lim A, Thompson KL, Rosenzweig BA, Sorbara L, Srivastava S, Salit ML.

BMC Genomics. 2018 Mar 6;19(1):180. doi: 10.1186/s12864-018-4496-1.

2.

Silencing the Snail-Dependent RNA Splice Regulator ESRP1 Drives Malignant Transformation of Human Pulmonary Epithelial Cells.

Walser TC, Jing Z, Tran LM, Lin YQ, Yakobian N, Wang G, Krysan K, Zhu LX, Sharma S, Lee MH, Belperio JA, Ooi AT, Gomperts BN, Shay JW, Larsen JE, Minna JD, Hong LS, Fishbein MC, Dubinett SM.

Cancer Res. 2018 Apr 15;78(8):1986-1999. doi: 10.1158/0008-5472.CAN-17-0315. Epub 2018 Feb 5.

PMID:
29431637
3.

Identification of a Human Airway Epithelial Cell Subpopulation with Altered Biophysical, Molecular, and Metastatic Properties.

Pagano PC, Tran LM, Bendris N, O'Byrne S, Tse HT, Sharma S, Hoech JW, Park SJ, Liclican EL, Jing Z, Li R, Krysan K, Paul MK, Fontebasso Y, Larsen JE, Hakimi S, Seki A, Fishbein MC, Gimzewski JK, Carlo DD, Minna JD, Walser TC, Dubinett SM.

Cancer Prev Res (Phila). 2017 Sep;10(9):514-524. doi: 10.1158/1940-6207.CAPR-16-0335. Epub 2017 Jul 28.

PMID:
28754664
4.

CancerLocator: non-invasive cancer diagnosis and tissue-of-origin prediction using methylation profiles of cell-free DNA.

Kang S, Li Q, Chen Q, Zhou Y, Park S, Lee G, Grimes B, Krysan K, Yu M, Wang W, Alber F, Sun F, Dubinett SM, Li W, Zhou XJ.

Genome Biol. 2017 Mar 24;18(1):53. doi: 10.1186/s13059-017-1191-5.

5.

Targeted Inhibition of EGFR and Glutaminase Induces Metabolic Crisis in EGFR Mutant Lung Cancer.

Momcilovic M, Bailey ST, Lee JT, Fishbein MC, Magyar C, Braas D, Graeber T, Jackson NJ, Czernin J, Emberley E, Gross M, Janes J, Mackinnon A, Pan A, Rodriguez M, Works M, Zhang W, Parlati F, Demo S, Garon E, Krysan K, Walser TC, Dubinett SM, Sadeghi S, Christofk HR, Shackelford DB.

Cell Rep. 2017 Jan 17;18(3):601-610. doi: 10.1016/j.celrep.2016.12.061.

6.

Combination Treatment with Apricoxib and IL-27 Enhances Inhibition of Epithelial-Mesenchymal Transition in Human Lung Cancer Cells through a STAT1 Dominant Pathway.

Lee MH, Kachroo P, Pagano PC, Yanagawa J, Wang G, Walser TC, Krysan K, Sharma S, John MS, Dubinett SM, Lee JM.

J Cancer Sci Ther. 2014 Nov;6(11):468-477. Epub 2014 Nov 15.

7.

Loss of miR125a expression in a model of K-ras-dependent pulmonary premalignancy.

Liclican EL, Walser TC, Hazra S, Krysan K, Park SJ, Pagano PC, Gardner BK, Larsen JE, Minna JD, Dubinett SM.

Cancer Prev Res (Phila). 2014 Aug;7(8):845-55. doi: 10.1158/1940-6207.CAPR-14-0063. Epub 2014 Jun 9.

8.

PGE2-driven expression of c-Myc and oncomiR-17-92 contributes to apoptosis resistance in NSCLC.

Krysan K, Kusko R, Grogan T, O'Hearn J, Reckamp KL, Walser TC, Garon EB, Lenburg ME, Sharma S, Spira AE, Elashoff D, Dubinett SM.

Mol Cancer Res. 2014 May;12(5):765-74. doi: 10.1158/1541-7786.MCR-13-0377. Epub 2014 Jan 27.

9.

IL-27 inhibits epithelial-mesenchymal transition and angiogenic factor production in a STAT1-dominant pathway in human non-small cell lung cancer.

Kachroo P, Lee MH, Zhang L, Baratelli F, Lee G, Srivastava MK, Wang G, Walser TC, Krysan K, Sharma S, Dubinett SM, Lee JM.

J Exp Clin Cancer Res. 2013 Nov 25;32:97. doi: 10.1186/1756-9966-32-97.

10.

A novel molecular pathway for Snail-dependent, SPARC-mediated invasion in non-small cell lung cancer pathogenesis.

Grant JL, Fishbein MC, Hong LS, Krysan K, Minna JD, Shay JW, Walser TC, Dubinett SM.

Cancer Prev Res (Phila). 2014 Jan;7(1):150-60. doi: 10.1158/1940-6207.CAPR-13-0263. Epub 2013 Nov 19.

11.

Elevated neutrophil gelatinase-associated lipocalin contributes to erlotinib resistance in non-small cell lung cancer.

Krysan K, Cui X, Gardner BK, Reckamp KL, Wang X, Hong L, Walser TC, Rodriguez NL, Pagano PC, Garon EB, Brothers JF 2nd, Elashoff D, Lee JM, Spira AE, Sharma S, Fishbein MC, Dubinett SM.

Am J Transl Res. 2013 Aug 15;5(5):481-96. eCollection 2013.

12.

The inflammatory tumor microenvironment, epithelial mesenchymal transition and lung carcinogenesis.

Heinrich EL, Walser TC, Krysan K, Liclican EL, Grant JL, Rodriguez NL, Dubinett SM.

Cancer Microenviron. 2012 Apr;5(1):5-18. doi: 10.1007/s12307-011-0089-0. Epub 2011 Sep 16.

13.

Elevated levels of CXC chemokine connective tissue activating peptide (CTAP)-III in lung cancer patients.

Lee G, Gardner BK, Elashoff DA, Purcell CM, Sandha HS, Mao JT, Krysan K, Lee JM, Dubinett SM.

Am J Transl Res. 2011 May 15;3(3):226-33. Epub 2011 Apr 2.

14.

Proinflammatory mediators upregulate snail in head and neck squamous cell carcinoma.

St John MA, Dohadwala M, Luo J, Wang G, Lee G, Shih H, Heinrich E, Krysan K, Walser T, Hazra S, Zhu L, Lai C, Abemayor E, Fishbein M, Elashoff DA, Sharma S, Dubinett SM.

Clin Cancer Res. 2009 Oct 1;15(19):6018-27. doi: 10.1158/1078-0432.CCR-09-0011. Epub 2009 Sep 29.

15.

Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin.

Reckamp KL, Gardner BK, Figlin RA, Elashoff D, Krysan K, Dohadwala M, Mao J, Sharma S, Inge L, Rajasekaran A, Dubinett SM.

J Thorac Oncol. 2008 Feb;3(2):117-24. doi: 10.1097/JTO.0b013e3181622bef.

16.

Inflammation, epithelial to mesenchymal transition, and epidermal growth factor receptor tyrosine kinase inhibitor resistance.

Krysan K, Lee JM, Dohadwala M, Gardner BK, Reckamp KL, Garon E, St John M, Sharma S, Dubinett SM.

J Thorac Oncol. 2008 Feb;3(2):107-10. doi: 10.1097/JTO.0b013e3181630ece. Review.

17.

Inflammation and lung carcinogenesis: applying findings in prevention and treatment.

Peebles KA, Lee JM, Mao JT, Hazra S, Reckamp KL, Krysan K, Dohadwala M, Heinrich EL, Walser TC, Cui X, Baratelli FE, Garon E, Sharma S, Dubinett SM.

Expert Rev Anticancer Ther. 2007 Oct;7(10):1405-21. Review.

PMID:
17944566
18.

Significance of cyclooxygenase-2 in prognosis, targeted therapy and chemoprevention of NSCLC.

Lee JM, Mao JT, Krysan K, Dubinett SM.

Future Oncol. 2007 Apr;3(2):149-53.

PMID:
17381414
19.

A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.

Reckamp KL, Krysan K, Morrow JD, Milne GL, Newman RA, Tucker C, Elashoff RM, Dubinett SM, Figlin RA.

Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3381-8.

20.

The potential and rationale for COX-2 inhibitors in lung cancer.

Krysan K, Reckamp KL, Sharma S, Dubinett SM.

Anticancer Agents Med Chem. 2006 May;6(3):209-20. Review.

PMID:
16712449
21.

Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer.

Dohadwala M, Yang SC, Luo J, Sharma S, Batra RK, Huang M, Lin Y, Goodglick L, Krysan K, Fishbein MC, Hong L, Lai C, Cameron RB, Gemmill RM, Drabkin HA, Dubinett SM.

Cancer Res. 2006 May 15;66(10):5338-45.

22.

Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer.

Dalwadi H, Krysan K, Heuze-Vourc'h N, Dohadwala M, Elashoff D, Sharma S, Cacalano N, Lichtenstein A, Dubinett S.

Clin Cancer Res. 2005 Nov 1;11(21):7674-82.

23.

Chemoprevention strategies with cyclooxygenase-2 inhibitors for lung cancer.

Mao JT, Cui X, Reckamp K, Liu M, Krysan K, Dalwadi H, Sharma S, Hazra S, Strieter R, Gardner B, Dubinett SM.

Clin Lung Cancer. 2005 Jul;7(1):30-9. Review.

PMID:
16098242
24.
25.

PGE2 confers survivin-dependent apoptosis resistance in human monocyte-derived dendritic cells.

Baratelli F, Krysan K, Heuzé-Vourc'h N, Zhu L, Escuadro B, Sharma S, Reckamp K, Dohadwala M, Dubinett SM.

J Leukoc Biol. 2005 Aug;78(2):555-64. Epub 2005 May 20.

PMID:
15908458
26.

Prostaglandin E2-dependent enhancement of tissue inhibitors of metalloproteinases-1 production limits dendritic cell migration through extracellular matrix.

Baratelli FE, Heuzé-Vourc'h N, Krysan K, Dohadwala M, Riedl K, Sharma S, Dubinett SM.

J Immunol. 2004 Nov 1;173(9):5458-66.

27.

Cyclooxygenase-2 modulates the insulin-like growth factor axis in non-small-cell lung cancer.

Põld M, Krysan K, Põld A, Dohadwala M, Heuze-Vourc'h N, Mao JT, Riedl KL, Sharma S, Dubinett SM.

Cancer Res. 2004 Sep 15;64(18):6549-55.

28.

Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer.

Krysan K, Dalwadi H, Sharma S, Põld M, Dubinett S.

Cancer Res. 2004 Sep 15;64(18):6359-62.

29.

Multifaceted roles of cyclooxygenase-2 in lung cancer.

Riedl K, Krysan K, Põld M, Dalwadi H, Heuze-Vourc'h N, Dohadwala M, Liu M, Cui X, Figlin R, Mao JT, Strieter R, Sharma S, Dubinett SM.

Drug Resist Updat. 2004 Jun;7(3):169-84. Review.

PMID:
15296859
30.

Cyclooxygenase-2-dependent expression of survivin in non-small cell lung cancer.

Krysan K, Dohadwala M, Luo J, Lin Y, Zhu L, Heuze-Vourc'h N, Goodglick L, Merchant F, Seligson D, Pold M, Strieter R, Sharma S, Dubinett S.

Chest. 2004 May;125(5 Suppl):140S. No abstract available.

PMID:
15136466
31.

Platelet derived growth factor (PDGF)-induced reactive oxygen species in the lens epithelial cells: the redox signaling.

Chen KC, Zhou Y, Xing K, Krysan K, Lou MF.

Exp Eye Res. 2004 Jun;78(6):1057-67.

PMID:
15109912
32.

Cyclooxygenase-2-dependent expression of angiogenic CXC chemokines ENA-78/CXC Ligand (CXCL) 5 and interleukin-8/CXCL8 in human non-small cell lung cancer.

Põld M, Zhu LX, Sharma S, Burdick MD, Lin Y, Lee PP, Põld A, Luo J, Krysan K, Dohadwala M, Mao JT, Batra RK, Strieter RM, Dubinett SM.

Cancer Res. 2004 Mar 1;64(5):1853-60.

33.

COX-2-dependent stabilization of survivin in non-small cell lung cancer.

Krysan K, Merchant FH, Zhu L, Dohadwala M, Luo J, Lin Y, Heuze-Vourc'h N, Põld M, Seligson D, Chia D, Goodglick L, Wang H, Strieter R, Sharma S, Dubinett S.

FASEB J. 2004 Jan;18(1):206-8. Epub 2003 Nov 3.

PMID:
14597555
34.

Abnormal interleukin 10Ralpha expression contributes to the maintenance of elevated cyclooxygenase-2 in non-small cell lung cancer cells.

Heuze-Vourc'h N, Zhu L, Krysan K, Batra RK, Sharma S, Dubinett SM.

Cancer Res. 2003 Feb 15;63(4):766-70.

35.

Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion.

Dohadwala M, Batra RK, Luo J, Lin Y, Krysan K, Pold M, Sharma S, Dubinett SM.

J Biol Chem. 2002 Dec 27;277(52):50828-33. Epub 2002 Oct 21.

36.

Regulation of human thioltransferase (hTTase) gene by AP-1 transcription factor under oxidative stress.

Krysan K, Lou MF.

Invest Ophthalmol Vis Sci. 2002 Jun;43(6):1876-83.

PMID:
12036993
37.

Identification and characterization of a new mammalian glutaredoxin (thioltransferase), Grx2.

Gladyshev VN, Liu A, Novoselov SV, Krysan K, Sun QA, Kryukov VM, Kryukov GV, Lou MF.

J Biol Chem. 2001 Aug 10;276(32):30374-80. Epub 2001 Jun 7.

38.

Regulation of thioltransferase expression in human lens epithelial cells.

Raghavachari N, Krysan K, Xing K, Lou MF.

Invest Ophthalmol Vis Sci. 2001 Apr;42(5):1002-8.

PMID:
11274078
39.

Primary structure of human matrilin-2, chromosome location of the MATN2 gene and conservation of an AT-AC intron in matrilin genes.

Muratoglu S, Krysan K, Balázs M, Sheng H, Zákány R, Módis L, Kiss I, Deák F.

Cytogenet Cell Genet. 2000;90(3-4):323-7.

PMID:
11124542
40.

Characterization and chromosome location of the mouse link protein gene (Crtl1).

Deák F, Mátés L, Krysan K, Liu Z, Szabó PE, Mann JR, Beier DR, Kiss I.

Cytogenet Cell Genet. 1999;87(1-2):75-9.

PMID:
10640815

Supplemental Content

Loading ...
Support Center